Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 185

1.

Dual targeting of the cyclin/Rb/E2F and mitochondrial pathways in mantle cell lymphoma with the translation inhibitor silvestrol.

Alinari L, Prince CJ, Edwards RB, Towns WH, Mani R, Lehman A, Zhang X, Jarjoura D, Pan L, Kinghorn AD, Grever MR, Baiocchi RA, Lucas DM.

Clin Cancer Res. 2012 Sep 1;18(17):4600-11. doi: 10.1158/1078-0432.CCR-12-0839. Epub 2012 Jul 12.

2.
3.

A cyclin-D1 interaction with BAX underlies its oncogenic role and potential as a therapeutic target in mantle cell lymphoma.

Beltran E, Fresquet V, Martinez-Useros J, Richter-Larrea JA, Sagardoy A, Sesma I, Almada LL, Montes-Moreno S, Siebert R, Gesk S, Calasanz MJ, Malumbres R, Rieger M, Prosper F, Lossos IS, Piris MA, Fernandez-Zapico ME, Martinez-Climent JA.

Proc Natl Acad Sci U S A. 2011 Jul 26;108(30):12461-6. doi: 10.1073/pnas.1018941108. Epub 2011 Jul 11.

4.

Sorafenib inhibits cell migration and stroma-mediated bortezomib resistance by interfering B-cell receptor signaling and protein translation in mantle cell lymphoma.

Xargay-Torrent S, López-Guerra M, Montraveta A, Saborit-Villarroya I, Rosich L, Navarro A, Pérez-Galán P, Roué G, Campo E, Colomer D.

Clin Cancer Res. 2013 Feb 1;19(3):586-97. doi: 10.1158/1078-0432.CCR-12-1935. Epub 2012 Dec 11.

5.

Antitumoral activity of lenalidomide in in vitro and in vivo models of mantle cell lymphoma involves the destabilization of cyclin D1/p27KIP1 complexes.

Moros A, Bustany S, Cahu J, Saborit-Villarroya I, Martínez A, Colomer D, Sola B, Roué G.

Clin Cancer Res. 2014 Jan 15;20(2):393-403. doi: 10.1158/1078-0432.CCR-13-1569. Epub 2013 Oct 31.

6.

Transcription and translation are primary targets of Pim kinase inhibitor SGI-1776 in mantle cell lymphoma.

Yang Q, Chen LS, Neelapu SS, Miranda RN, Medeiros LJ, Gandhi V.

Blood. 2012 Oct 25;120(17):3491-500. doi: 10.1182/blood-2012-02-412643. Epub 2012 Sep 6.

7.

Increased proteasome degradation of cyclin-dependent kinase inhibitor p27 is associated with a decreased overall survival in mantle cell lymphoma.

Chiarle R, Budel LM, Skolnik J, Frizzera G, Chilosi M, Corato A, Pizzolo G, Magidson J, Montagnoli A, Pagano M, Maes B, De Wolf-Peeters C, Inghirami G.

Blood. 2000 Jan 15;95(2):619-26.

8.

Mantle cell lymphoma cells express predominantly cyclin D1a isoform and are highly sensitive to selective inhibition of CDK4 kinase activity.

Marzec M, Kasprzycka M, Lai R, Gladden AB, Wlodarski P, Tomczak E, Nowell P, Deprimo SE, Sadis S, Eck S, Schuster SJ, Diehl JA, Wasik MA.

Blood. 2006 Sep 1;108(5):1744-50. Epub 2006 May 11.

9.

Combined administration of rituximab and on 013105 induces apoptosis in mantle cell lymphoma cells and reduces tumor burden in a mouse model of mantle cell lymphoma.

Prasad A, Shrivastava A, Papadopoulos E, Kuzontkoski PM, Reddy MV, Gillum AM, Kumar R, Reddy EP, Groopman JE.

Clin Cancer Res. 2013 Jan 1;19(1):85-95. doi: 10.1158/1078-0432.CCR-12-1425. Epub 2012 Nov 1.

10.

Cell cycle alterations in the blastoid variant of mantle cell lymphoma (MCL-BV) as detected by gene expression profiling of mantle cell lymphoma (MCL) and MCL-BV.

de Vos S, Krug U, Hofmann WK, Pinkus GS, Swerdlow SH, Wachsman W, Grogan TM, Said JW, Koeffler HP.

Diagn Mol Pathol. 2003 Mar;12(1):35-43.

PMID:
12605034
11.

Specific lentiviral shRNA-mediated knockdown of cyclin D1 in mantle cell lymphoma has minimal effects on cell survival and reveals a regulatory circuit with cyclin D2.

Klier M, Anastasov N, Hermann A, Meindl T, Angermeier D, Raffeld M, Fend F, Quintanilla-Martinez L.

Leukemia. 2008 Nov;22(11):2097-105. doi: 10.1038/leu.2008.213. Epub 2008 Aug 7.

PMID:
18685613
13.

Mechanism of the antitumoral activity of deferasirox, an iron chelation agent, on mantle cell lymphoma.

Vazana-Barad L, Granot G, Mor-Tzuntz R, Levi I, Dreyling M, Nathan I, Shpilberg O.

Leuk Lymphoma. 2013 Apr;54(4):851-9. doi: 10.3109/10428194.2012.734614. Epub 2013 Jan 2.

PMID:
23020673
14.
16.

Styryl sulfonyl compounds inhibit translation of cyclin D1 in mantle cell lymphoma cells.

Prasad A, Park IW, Allen H, Zhang X, Reddy MV, Boominathan R, Reddy EP, Groopman JE.

Oncogene. 2009 Mar 26;28(12):1518-28. doi: 10.1038/onc.2008.502. Epub 2009 Feb 9.

PMID:
19198627
17.

A defect of the INK4-Cdk4 checkpoint and Myc collaborate in blastoid mantle cell lymphoma-like lymphoma formation in mice.

Vincent-Fabert C, Fiancette R, Rouaud P, Baudet C, Truffinet V, Magnone V, Guillaudeau A, Cogné M, Dubus P, Denizot Y.

Am J Pathol. 2012 Apr;180(4):1688-701. doi: 10.1016/j.ajpath.2012.01.004. Epub 2012 Feb 9.

PMID:
22326754
18.

Differential PAX5 levels promote malignant B-cell infiltration, progression and drug resistance, and predict a poor prognosis in MCL patients independent of CCND1.

Teo AE, Chen Z, Miranda RN, McDonnell T, Medeiros LJ, McCarty N.

Leukemia. 2016 Mar;30(3):580-93. doi: 10.1038/leu.2015.140. Epub 2015 May 15.

19.

Induction of apoptosis and down regulation of cell cycle proteins in mantle cell lymphoma by flavopiridol treatment.

Venkataraman G, Maududi T, Ozpuyan F, Bahar HI, Izban KF, Qin JZ, Alkan S.

Leuk Res. 2006 Nov;30(11):1377-84. Epub 2006 Apr 19.

PMID:
16624404
20.

Antiproliferative and proapoptotic activity of GUT-70 mediated through potent inhibition of Hsp90 in mantle cell lymphoma.

Jin L, Tabe Y, Kimura S, Zhou Y, Kuroda J, Asou H, Inaba T, Konopleva M, Andreeff M, Miida T.

Br J Cancer. 2011 Jan 4;104(1):91-100. doi: 10.1038/sj.bjc.6606007. Epub 2010 Dec 7.

Supplemental Content

Support Center